Growth confirmed; Q2 headwinds flagged

Honasa's Q1 was strong across the board — ₹756 Cr revenue beat the high-teens CAGR target, PAT more than doubled on margin expansion, and focus categories (face wash, sunscreen, hair care) drove 35% growth at 85% portfolio contribution. Yet on the call, management maintained its 5-year guidance rather than raising it. That gap — between the beat and the caution — is the story of the quarter.

Management laid three flags. First: Q1 is seasonally strong. Face wash and sunscreen categories peak in summer, contributing ~50 basis points of EBITDA margin lift this quarter. Management expects Q2 to show sequential moderation as those categories fade. Second: cost inflation will bite harder in H2. Crude oil and packaging material inflation are real; the company absorbed the impact in Q1 through inventory management and took calibrated price increases at quarter-end. 'The real impact of it will be Q2,' CFO Ramanpreet Sohi warned. Third: younger brands have hit a ceiling. Aqualogica, BBlunt, Dr. Sheth's, and Reginald are all growing at 40%+ but are capped at ₹150–200 Cr annual run-rate. Management now acknowledges this is a repositioning challenge, not just a timing one.

Younger brands ceiling acknowledged. Prior roadmaps assumed continuous scale. Now Aqualogica, BBlunt, Dr. Sheth's, Reginald all sit at ₹150–200 Cr ARR despite 40%+ growth — management flagged repositioning needed to unlock next leg (GenZ relaunch for Aqualogica, refinements for BBlunt and Dr. Sheth's over 6–9 months).

Mamaearth trajectory upgraded in tone. High-teens growth delivered in Q1 (vs. prior double-digit CAGR baseline); Rice face wash now #1 in category, Rosemary shampoo >₹100 Cr ARR. Distribution gains across Modern Trade and General Trade signal share capture.

Fragrance strategy evolved post-failure. Mamaearth's prior fragrance attempt failed on poor product-market fit. The company learned and is now launching FIKN as a standalone brand, distinct from Mamaearth, with 1.5 years of R&D backing.

Fluence Pharma still in diligence. Nutraceuticals deal announced but has not closed; Honasa Health subsidiary created for strategic oversight, but integration timeline unproven.

The stock popped +4.97% on day 1 post-result announcement (31.9% delivery), but the move faded by day 3 (−0.92%). That reversal tells a story: the market priced in the beat but got sceptical on the lack of guidance raise. It's now positioned at ₹476.1, up 91.67% from its 52-week low and just 6.61% off its all-time high. The trend is bullish (above SMA20, SMA50, SMA200), but RSI sits at 64.1 (neutral territory).

Ownership tells a nuanced story. FII are quietly selling (−10 basis points QoQ, down from 15.50% in Q2 FY26 to 13.64% now), but DII added 234 basis points this quarter (21.58% vs. 19.24% in Q4), suggesting domestic institutional confidence holding even as foreign money rotates. Promoters steady at 35.47%.

In bulk/block trades, the most significant move was Sofina Ventures (Unilever's VC arm, a major early Honasa investor) selling 41.78 lakh shares @ ₹424 on May 22, 2026. Sofina at ₹424 vs. stock now ₹476 signals a VC taking profits after the strong run-up, not a red flag on fundamentals. Other traders (Microcurves, QE Securities, NK Securities) also active in mid-May, suggesting typical position rebalancing.